Incyte Corp logo

Incyte Corp

INCY
Healthcare|Biotechnology|USA
$93.59
-1.27 (-1.34%)
DCF (FCF)
$55.64
Tangible Book
$24.78
Graham Number
$61.53
Earnings Power
$50.38

Analyst Ratings

Firm / AnalystRatingPrice TargetDate

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812" ], "revenue_estimate": [ 5568.56, 6180.18, 6360.68 ], "ebit_estimate": [ 1877.79, 2349.66, 2542.99 ], "ebitda_estimate": [ 1863.43, 2448.34, 2650.59 ], "net_income_estimate": [ 1552.81, 1913.32, 1984.25 ], "per_share_eps_estimate": [ 6.42, 7.5, 7.83 ], "eps_nri_estimate": [ 7.59, 8.96, 9.28 ], "dividend_estimate": [ null, null, null ], "book_value_per_share_estimate": [ 33.47, 42.93, 53.23 ], "pretax_income_estimate": [ 1967.18, 2530.43, 2741.52 ], "operating_cash_flow_per_share_estimate": [ 8.57, 9.89, 10.6 ], "roa_estimate": [ 16, 14.63, 10.75 ], "roe_estimate": [ 22.69, 21.19, 17.65 ], "gross_margin_estimate": [ 92.51, 92.37, 92.01 ], "operating_cash_flow_estimate": [ 1753.29, 2023.35, 2168.6 ], "pettm_estimate": [ 14.6, 12.49, 11.96 ], "long_term_growth_rate_mean": 11.62, "long_term_revenue_growth_rate_mean": "7.71", "future_per_share_eps_estimate_growth": 7.87, "future_eps_nri_estimate_growth": 11.62, "future_revenue_estimate_growth": 7.71, "future_ebit_estimate_growth": 16.08, "future_ebitda_estimate_growth": 16.2, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 16.28, "future_pretax_income_estimate_growth": 19.11, "future_book_value_per_share_estimate_growth": 27.05, "future_roa_estimate_growth": -18.63, "future_roe_estimate_growth": -15.18, "future_gross_margin_estimate_growth": -0.26, "future_operating_cash_flow_per_share_estimate_growth": 14.68 }
quarterly
{ "date": [ "202603", "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 1233.07, 1361.51, 1443.4, 1538.88, 1369.41, 1466.14, 1516.8, 1589.01 ], "ebit_estimate": [ 349.74, 449.56, 501.66, 556.68, 499.06, 567.52, 583.72, 618.74 ], "ebitda_estimate": [ 249.96, 391.67, 514.94, 628.39, null, null, null, null ], "net_income_estimate": [ 283.59, 369.59, 423.96, 466.28, 406.61, 459.32, 471.8, 498.76 ], "per_share_eps_estimate": [ 1.1, 1.56, 1.76, 1.91, null, null, null, null ], "eps_nri_estimate": [ 1.44, 1.83, 2.08, 2.23, 1.96, 2.21, 2.4, 2.83 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ 373.24, 479.01, 541.08, 587.73, 528.06, 596.52, 612.72, 647.74 ], "operating_cash_flow_per_share_estimate": [ 1.18, 1.76, 2.26, 2.71, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 92.52, 92.74, 92.5, 92.38, null, null, null, null ], "operating_cash_flow_estimate": [ 241.41, 360.07, 462.36, 554.43, null, null, null, null ], "pettm_estimate": [ 14.83, null, null, null, null, null, null, null ], "long_term_growth_rate_mean": 11.62, "long_term_revenue_growth_rate_mean": "7.71", "future_per_share_eps_estimate_growth": 7.87, "future_eps_nri_estimate_growth": 11.62, "future_revenue_estimate_growth": 7.71, "future_ebit_estimate_growth": 16.08, "future_ebitda_estimate_growth": 16.2, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 16.28, "future_pretax_income_estimate_growth": 19.11, "future_book_value_per_share_estimate_growth": 27.05, "future_roa_estimate_growth": -18.63, "future_roe_estimate_growth": -15.18, "future_gross_margin_estimate_growth": -0.26, "future_operating_cash_flow_per_share_estimate_growth": 14.68 }

News

2026-03-30 23:30:09
2026-03-30 20:31:41
2026-03-28 20:00:02
2026-03-26 14:30:09
2026-03-25 16:31:56
2026-03-25 14:00:02
2026-03-25 11:00:35
2026-03-20 15:00:01
2026-03-17 12:29:15
2026-03-16 13:30:29
2026-03-11 17:00:37
2026-03-10 18:02:53
2026-03-09 11:01:02
2026-03-07 14:55:32
2026-03-07 00:30:20
2026-03-06 22:25:33
2026-03-06 22:00:04
2026-03-05 14:36:17
2026-03-02 21:01:13
2026-02-18 16:04:42